RIN Data

This rule will revise 21 CFR 202.1 to eliminate the option for prescription drug advertisements broadcast through media such as radio or television to fulfill the statutory brief summary requirement in section 502(n) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) by disclosing risk, contraindication, and other safety information in another source beyond the advertisement itself.

Statement of Need:

Until relatively recently, Direct-to-Consumer (DTC) broadcast advertisements for prescription drugs were rare, in part because drug companies had not been advised by FDA how they could meet the adequate provision requirement for dissemination of the FDA-approved labeling in connection with broadcast ads. In 1999, FDA issued a final guidance document, that described an approach to fulfill the adequate provision requirement for broadcast advertisements. The approach created a loophole that resulted in certain important information being hidden behind 1-800 numbers, print inserts, and websites, rather than being included in the broadcast advertisement.

The proliferation of DTC advertising across television and digital platforms has created potential patient confusion and harm from inappropriate demand for medications, distorting the doctor-patient relationship leading to misalignment of therapeutic choices with actual patient needs, and the misallocation of healthcare resources and government overspending. FDA proposes revising the prescription drug advertising regulation to require DTC ads broadcast through media such as radio and television to disclose all relevant risk and safety information to consumers within the confines of the ad itself rather than referring consumers to an external source where they can request the full FDA-approved labeling. This action does not constitute a ban or unreasonable imposition on DTC drug advertising, but would instead require complete and accurate safety, contraindication, and other risk information in DTC prescription drug advertisements, so that patients and consumers can make fully informed decisions.

Summary of the Legal Basis:

FDA has authority to promulgate rules governing the promotion of prescription drugs under Section 502(n) of the FD&C Act [21 U.S.C. 352(n)], which states that promotional material shall include "such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations[.]" FDA has set forth regulations under 502(n) at 21 CFR 202.1, including the "adequate provision" language at issue here.  Id. at 202.1(e)(1)(i)(B).

Alternatives:

Removing the "adequate provision" loophole permitting the disclosure of "all necessary information related to side effects and contraindications" in a location other than the promotional material is the only option to effectuate the goals and direction of the September 9, 2025, Presidential Memorandum instructing HHS and FDA to "take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law."

Anticipated Costs and Benefits:

FDA anticipates that this rule, if finalized, will result in regulatory costs.  Industry will face costs of either: 1) purchasing additional advertising time to include required product safety information, 2) dedicating additional advertising time within current advertising time slots toward the newly required information, or 3) the opportunity cost of choosing not to advertise if the cost of inclusion of all newly required safety information induces a decrease or cessation of product advertising.  To provide context for the magnitude of such potential costs, we note that, in 2023, the top ten pharmaceutical companies spent a combined $13.8 billion on the promotion of drugs directed at U.S. consumers and physicians (source: CSRxP Analysis: Direct-To-Consumer Advertising Report. (2025).  In CSRxP.org. The Campaign for Sustainable Rx Pricing. https://www.csrxp.org/wp-content/uploads/2025/04/CSRxP-Analysis-Direct-to-Consumer-Advertising-Report.pdf).  Given the potential impact on advertising spending, we expect this rule to be economically significant, with annual costs exceeding $100 million for at least one year.  The benefits of this rule are in providing patients more complete safety information during all advertisements covered by the rule, thus improving consumer understanding when they participate in healthcare decision making.

Risks:

TBD